A large National Institutes of Health-sponsored trial is underway to determine if the drug is beneficial for patients with preserved LVEE
and will build on a small study in which 30 patients with HFPEF showed improved myocardial function after treatment with spironolactone.
Anergia tended to correlate with worse functional capacity and worse quality of life, but not to a lower LVEE
Compared to those without it, patients with anergia spent less time engaged in moderate-level exercise, and their peak levels of exercise were lower.
Investigators adjusted their data to account for a large number of covariables, including age, sex, number of grafts, LVEE
diabetes, smoking history; and previous MI.